In today’s recent session, 0.63 million shares of the Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) have been traded, and its beta is 0.13. Most recently the company’s share price was $1.2, and it changed around $0.06 or 5.26% from the last close, which brings the market valuation of the company to $11.81M. BCLI at last check was trading at a discount to its 52-week high of $6.45, offering almost -437.5% off that amount. The share price’s 52-week low was $0.72, which indicates that the recent value has risen by an impressive 40.0% since then. We note from Brainstorm Cell Therapeutics, Inc’s average daily trading volume that its 10-day average is 0.29 million shares, with the 3-month average coming to 1.40 million.
Brainstorm Cell Therapeutics, Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended BCLI as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Brainstorm Cell Therapeutics, Inc is expected to report earnings per share of -0.33 for the current quarter.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) trade information
Instantly BCLI has been showing a green trend so far today with a performance of 5.26% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -76.64% year-to-date, but still up 7.14% over the last five days. On the other hand, Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) is 6.19% up in the 30-day period. We can see from the shorts that 0.46 million shares have been sold at a short interest cover period of 0.15 day(s).
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 32.00%. Brainstorm Cell Therapeutics, Inc earnings are expected to increase by 30.74% in 2025, but the outlook is positive 29.48% per year for the next five years.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc’s next quarterly earnings report is expected to be released on 2025-May-15.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 15.98% of Brainstorm Cell Therapeutics, Inc shares, and 12.89% of them are in the hands of institutional investors. The stock currently has a share float of 15.34%. Brainstorm Cell Therapeutics, Inc stock is held by 35.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 11.1179% of the shares, which is about 7.92 million shares worth $2.68 million.
VANGUARD GROUP INC, with 2.1212% or 1.51 million shares worth $0.51 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of May 31, 2025 . The former held 31.41 shares worth $37637.0, making up 0.32% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 26.73 shares worth around $32030.0, which represents about 0.27% of the total shares outstanding.
